CK
Highly rated in
34
conditions

Dr. Craig M. Kessler

MedStar Georgetown University Hospital
Washington, DC
Highly rated in
34
conditions
Specialties:Hematology Oncology | Hematology | Oncology
Experience:50 Years
Accepts:New PatientsMedicare
Highly rated in
34
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Craig M. Kessler's experience treating your condition:
About Dr. Craig M. Kessler

Craig Kessler is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Kessler has been practicing medicine for over 50 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in District of Columbia. Kessler is currently accepting new patients.

His clinical research consists of co-authoring 146 peer reviewed articles and participating in 10 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Craig M. Kessler it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Craig M. Kessler accepts the following insurance:

  •  Ambetter
  •  CareFirst
Call to see if your plan is accepted.
Locations
3800 Reservoir Rd Nw, Washington, DC 20007
Background & Education
Graduate Institution
Tulane University School Of Medicine, 1973
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in DC
Hospital Affiliations
MedStar Georgetown University Hospital
Sibley Memorial Hospital
Suburban Hospital
Languages Spoken
English
French
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Enrollment Status: Completed
Publish Date: September 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: ItacitinibRuxolitinib
Study Phase: Phase 2
Research Tissue Bank
Enrollment Status: Completed
Publish Date: July 05, 2019
Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A
Enrollment Status: Completed
Publish Date: January 19, 2021
Intervention Type: Biological
Study Phase: Phase 3
Molecular Biology of Familial Myeloproliferative Disorders
Enrollment Status: Completed
Publish Date: September 05, 2017
Biomarkers Serum Collection Methodology Pilot Study
Enrollment Status: Completed
Publish Date: July 24, 2012
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia A
Enrollment Status: Terminated
Publish Date: February 10, 2017
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
View 9 Less Clinical Trials -
154 Total Publications
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Journal: Platelets
Published: November 04, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
BL
Dr. Benjamin P. Levy
Oncology | Hematology Oncology | Hematology
Highly rated in
10
conditions
Oncology
Hematology Oncology
Hematology

Johns Hopkins Health System

Sibley Memorial Hospital

5255 Loughboro Rd Nw, 
Washington, DC 
 2.5 mi

Benjamin Levy is an Oncologist and a Hematologist Oncology expert in Washington, Washington, D.c.. Levy has been practicing medicine for over 21 years and is highly rated in 10 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. He is licensed to treat patients in Maryland and New York. Levy is currently accepting new patients.

AS
Dr. Alexander I. Spira
Oncology | Hematology Oncology | Hematology
Highly rated in
64
conditions
Oncology
Hematology Oncology
Hematology

Inova

Virginia Cancer Specialists, P.C.

8613 Lee Hwy # 200n, 
Fairfax, VA 
 9.4 mi

Alexander Spira is an Oncologist and a Hematologist Oncology expert in Fairfax, Virginia. Spira has been practicing medicine for over 26 years and is highly rated in 64 conditions, according to our data. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, Tissue Biopsy, and Orchiectomy. He is licensed to treat patients in Virginia. Spira is currently accepting new patients.

RB
Dr. Robert A. Brodsky
Hematology | Oncology
Highly rated in
31
conditions
Hematology
Oncology

Johns Hopkins Health System

Johns Hopkins University

600 N Wolfe St, 
Baltimore, MD 
 37.1 mi

Robert Brodsky is a Hematologist and an Oncologist in Baltimore, Maryland. Brodsky has been practicing medicine for over 34 years and is highly rated in 31 conditions, according to our data. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, Anemia, and Bone Marrow Transplant. He is licensed to treat patients in Maryland. Brodsky is currently accepting new patients.